The rapidly increasing incidence of type 1 diabetes implies that environmental factors are involved in the pathogenesis. Enteroviruses are among the suspected environmental triggers of the disease, and the interest in exploring the possibilities to develop vaccines against these viruses has increased. Our objective was to identify enterovirus serotypes which could be involved in the initiation of the disease process by screening neutralizing antibodies against 41 different enterovirus types in a unique longitudinal sample series from a large prospective birth-cohort study. The study participants comprised 183 case children testing persistently positive for at least two diabetespredictive autoantibodies and 366 autoantibody-negative matched control children. Coxsackievirus B1 was associated with an increased risk of β-cell autoimmunity. This risk was strongest when infection occurred a few months before autoantibodies appeared and it was attenuated by the presence of maternal antibodies against the virus. Two other Coxsackieviruses, B3 and B6, were associated with a reduced risk, with an interaction pattern suggesting immunological crossprotection against Coxsackievirus B1. These results support previous observations suggesting that the group B Coxsackieviruses are associated with the risk of type 1 diabetes. The clustering of the risk and protective viruses to this narrow phylogenetic lineage supports the biological plausibility of this phenomenon.
INTRODUCTION
Enteroviruses have been linked to type 1 diabetes in a number of previous studies (for reviews, see (1, 2) ). The recent discovery of diabetes-associated polymorphisms in the innate immune system receptor for enteroviruses (IFIH1) has further increased the interest in the role of enterovirus infections in the pathogenesis of the disease. (3) However, this association has not been observed in all studies and the causal relationship has remained open.
More than 100 different enterovirus serotypes have been identified, which vary in their binding to various cellular receptors and in their ability to infect different cell types and organs.
Consequently, different serotypes cause a diverse spectrum of diseases. The classical enterovirus disease, poliomyelitis, is caused by three serotypes, polioviruses 1, 2 and 3 which have a strong tropism for motoneurons in the spinal cord. This tropism is explained by the expression of the poliovirus receptor (PVR, CD166) on these cells. The virus spreads to the motoneurons in about 1% of infected individuals causing paralytic disease. Similarly, some other enteroviruses including the six Coxsackievirus B (CBV) serotypes seem to have a tropism for human pancreatic islets in vitro (4) (5) (6) (7) and in vivo, (8) (9) (10) possibly because islet cells express the Coxsackie-adenovirus receptor (CAR), which is the major receptor for CBVs (11). The identification of the enterovirus serotypes which may induce the disease process leading to type 1 diabetes is important since it would enable further studies on the mechanisms of enterovirus-induced β-cell damage, and would pave the way for the development of a preventive vaccine. The lack of this information could also explain the variable results from previous studies which have been based on assays detecting several different enterovirus types as a group (2, 12) . Despite the importance of this topic, large-scale systematic studies aimed at identifying diabetogenic enterovirus serotypes have not been performed. Previous reports, which have been based on case reports and small patient series, suggest that the CBV group Page 4 of 38 Diabetes viruses may include diabetogenic serotypes (1) , but also certain echovirus serotypes have been linked to type 1 diabetes. (13) Here, the role of enterovirus infections was studied using the birth cohort samples systematically collected in the prospective Diabetes Prediction and Prevention (DIPP) study in Finland. By screening for the presence of neutralizing antibodies directed against a panel of 41 enterovirus serotypes, we assessed the association between each individual serotype and the appearance of diabetes-predictive autoantibodies. This made it possible to study the timerelationship between infection and initiation of the autoimmune process. This is the first large and systematic study aimed at the identification of diabetogenic enterovirus types at the time when the process appears to start.
RESEARCH DESIGN AND METHODS

Subjects
The study population was derived from the DIPP study. (14) Families with children carrying increased genetic risk for type 1 diabetes, defined by cord-blood HLA typing, were invited to participate in prospective follow-up starting from birth. Blood samples were drawn at the ages of 3, 6, 12, 18, and 24 months and once a year thereafter. All follow-up samples were screened for islet cell antibodies (ICA), and if a child seroconverted to positivity for ICA, autoantibodies to insulin (IAA), glutamic acid decarboxylase (GADA), and the tyrosine phosphatase-related insulinomaassociated 2 molecule (IA-2A) were also analyzed from all follow-up samples. Written consent was obtained from each family whose child took part, and the study was approved by the Ethical Committees of the Pirkanmaa Hospital and the Northern Ostrobothnia Hospital districts.
Our study was a nested case-control study (Figure 1 ) using the following criteria to select case and control children. First, case children had turned permanently positive for two or more diabetespredictive autoantibodies and/or progressed to clinical type 1 diabetes. Two control children were selected for each case child. They all remained non-diabetic and autoantibody-negative for at least 2 years following the earliest detection of autoantibodies in the corresponding case child and were matched for time of birth (± 1 month except in 12 children ± 2 months), gender (60% were boys), HLA-DQB1 genotype and region. The final study cohort included 183 case and 366 control children born during the period from 1995 to 2006 and having an average age of 31 months (range 5-122 months) at initial seroconversion to autoantibody positivity (Supplementary Tables 1-2) . One hundred nineteen case children progressed to type 1 diabetes by the end of July 2011.
HLA Genotyping
An analysis of the HLA-DQB1 genotype was performed from cord blood to identify selected alleles (DQB1*02, *03:01, *03:02, and *06:02/3) associated with susceptibility to or protection against 96% and those of the IA-2A assay 72% and 100%, respectively. The diagnosis of type 1 diabetes was based on the WHO criteria.
Cells
Viruses were isolated, cultivated and seroneutralization assays were performed using the following cell lines: A549, Vero, RD, and GMK, of which the three first cell lines were purchased from ATCC whereas GMK was acquired from the National Institute for Health and Welfare, Finland.
Neutralizing antibodies against various enterovirus serotypes
Neutralizing antibodies were measured in serum or plasma against a total of 44 enterovirus strains representing 41 serotypes. Most of these viruses were isolated from DIPP children and from hospital patients in Finland and Sweden. All strains were plaque purified and sequenced in their VP1 region for serotyping. (18) Most of the viruses were analyzed using a standard plaque neutralization assay, (19, 20) while viruses that did not form clear plaques were analyzed using a microneutralization assay (Supplementary Table 4 ). All samples were screened using 1:4 and 1:16 dilutions. Inhibition was considered to be significant when the serum reduced the number of plaques more than 75% (plaque assay) or inhibited the ability of the virus to kill cells (microneutralization assay).
The identification of diabetogenic serotypes was based on a step-wise strategy ( Figure 1) . First, the neutralizing antibodies were analyzed in the samples where autoantibodies were detected for the first time in case children and in the corresponding samples in control children (cross-sectional analysis). All samples showing titers greater or equal to 1:4 were considered positive. In the next step, neutralizing antibodies were screened in samples from earlier time points (longitudinal analyses) for those enterovirus serotypes which were associated with diabetes risk at the crosssectional primary screening step. These longitudinal analyses made it possible to diagnose infections by virus antibody seroconversions observed between two consecutive follow-up samples (Supplementary Fig. 1 ). These earlier time points included samples taken 6 and 12 months before the initial seroconversion to autoantibody positivity (Fig. 1 ). The mean age and age range at these time points are shown in Supplementary Table 5 . Some samples were collected from the children at such a young age, that they possibly contained maternal antibodies. Cord blood samples were therefore analyzed in these children, and when the presence of maternal antibodies could bias a positive result the sample was considered negative. In addition, cord blood samples and samples taken at the age of 18 months were analyzed from all children for CBV1 antibodies. The following definitions were used to diagnose an acute infection: the main definition was based on "Sensitive diagnostic criteria" where both transient and permanent antibody seroconversions were counted (if the child had serial transient seroconversions against the same virus only the first one was counted).
The results were confirmed using more strict "Specific diagnostic criteria" where acute infections were diagnosed by the following criteria: a seroconversion from titer < 1:4 (seronegative) to 1:4 or higher (seropositive), a titer of 1:16 in at least one of the following samples and all subsequent samples positive.
Statistical Analyses
The primary analysis method was conditional logistic regression using the one-to-two age, gender, HLA and region matched case-control triplets. Data from matched case-control pairs and triplets were analyzed using Stata 8·2 (StataCorp, College Station, TX, USA) which allows for variable matching ratios of cases to controls. Conditional logistic regression was used to estimate the odds ratios (OR) with exact 95% confidence intervals (CI), and two-sided P values for univariate point estimates and multivariate modeling, to assess the association between enterovirus antibodies and diabetes-predictive autoantibodies. In the first phase, a cross-sectional analysis was carried out using data on the prevalence of enterovirus serotypes at the time point when the first diabetespredictive autoantibodies were detected. The duration of exclusive and total breast-feeding was entered into a multivariate analysis to estimate adjusted odds ratios. Second, to study the temporal profile of the associations detected in these cross-sectional analyses, infections occurring during all longitudinal time points before the detection of predictive autoantibodies were analyzed. The time was classified into three periods (simultaneously with the first detection of autoantibodies, 6 months before autoantibodies and 12 months or longer before autoantibodies), and the infections were diagnosed using both the sensitive and specific criteria described above. Third, the impact of the chronology of infections caused by different serotypes on the risk of β-cell autoimmunity was analyzed using the longitudinal data. Fourth, interactions between different serotypes were analyzed by studying the effect of different virus combinations. In addition to the raw P values the P values which have been corrected for the number of comparisons made (Bonferroni's correction) are presented.
RESULTS
Seroprevalences of coxsackievirus B1, B3 and B6 show a cross-sectional association with the risk to develop autoantibodies
Neutralizing antibodies were initially screened against 41 enterovirus serotypes in the first sample positive for diabetes-predictive autoantibodies. The conditional logistic regression analyses showed that CBV1 antibodies were more frequent in the cases than in the control children (59.0% vs.
50.1%; OR 1.5, 95% CI 1.0-2.2; P=0.04) suggesting that an infection with this enterovirus is associated with an increased risk of β-cell autoimmunity ( Table 1 ). The statistical significance disappears if the P value is multiplied by the number of tested serotypes (N=41). The high seroprevalence of CBV1 in the control children (50.1%) indicates that this enterovirus is a common serotype in the population studied. Only one case and one control child were negative for all 41 tested enterovirus serotypes (median number of positive serotypes was nine in both groups).
Neutralizing antibodies to two closely related serotypes, CBV3 and CBV6, were less frequent in cases than in control children indicating a strong protective association for CBV3 (5.8% vs. 12.8%;
OR 0.4, 95% CI 0.2-0.8; P=0·01) and a weaker protective association for CBV6 (26.6% vs. 35.3%;
Page 9 of 38 Diabetes OR 0.6, 95% CI 0.4-1.0; P=0.04) ( Table 1) . As above, the statistical significance disappears if these P values are multiplied by the number of tested serotypes. However, the fact that the protective serotypes were the closest genetically to CBV1 (Fig. 2) , and no protective association was seen for more distant strains among the 41 analyzed, suggests that these findings reflect a true biological phenomenon. In fact, they support the plausible hypothesis that there is some immunological crossprotection between these closely related enterovirus types. The analysis of potential interactions between CBV1 and the other CBV serotypes indicated a clear risk effect when the child had experienced CBV1 alone without these protective serotypes (OR 2.5, 95% CI 1.4-4.7; P=0.003) while children infected by both CBV1 and one or more of the protective serotypes were not at risk (Table 2 and Supplementary Table 6 ).
The risk association of CVB1 and the protective association of CBV3 and CBV6 were also seen in the sub-cohort of 119 children who progressed to clinical type 1 diabetes (OR for CBV1 was 1.8, 95% CI 1.1-2.9; P=0.025), both among boys and girls, and in different age groups (data not shown). The effects of CBV1 and CBV3 remained significant after adjustment for the duration of breast-feeding and the number of older siblings while the effect of CBV6 became non-significant (a clear trend was observed also for CBV6, Supplementary Table 7 ).
The coxsackievirus B1 risk association was confirmed in longitudinal analyses before the appearance of the first autoantibodies in case children
The timing of infection with CBV1 was further assessed in a longitudinal analysis by detecting seroconversions in the neutralizing antibodies between consecutive follow-up samples collected before the first autoantibody-positive sample. The results showed an increased risk of autoantibody positivity when a CBV1 infection preceded the autoantibody appearance (Table 3 ). This association was strongest when CBV1 infections preceded the first autoantibody-positive sample by a few months, and it was observed using both the sensitive and strict infection criteria. The association was also seen in the subgroup of children who progressed to clinical type 1 diabetes.
Chronological order of coxsackievirus B infections
When the longitudinal data were analyzed to study the impact of the order of infections with CBV1 and the protective CBV serotypes, some trends suggesting a potential order effect were observed.
When CBV1 was the first infecting serotype to occur, the children were at risk of developing autoantibodies whereas when CBV3 or CBV6 infection occurred first, the risk of developing autoantibodies was lower (Supplementary Table 8 ). This again supports the conclusion that infection by CBV3 or CBV6 provides some immunological protection from the diabetogenic effect of CBV1.
Maternal antibodies modulate the risk effect of coxsackievirus B1
The cord blood samples and samples taken at the age of 18 months were analyzed in order to explore whether protective maternal CBV1 antibodies in cord blood can modulate the risk association of CBV1 infections in young infants. The risk association was found to be strongest in the group who experienced CBV1 without maternal CBV1 antibodies (2.6; 95% CI 1.1-5.9;
P=0.02) ( Table 4) .
DISCUSSION
This case-control study nested in the DIPP birth cohort is the first systematic study aimed at identifying enterovirus subtypes possibly associated with the induction of β-cell autoantibodies.
The study has several unique strengths. First, it is based on the analysis of neutralizing antibodies which is the most reliable way to diagnose prior infection caused by a given enterovirus serotype.
Second, it covers a large number of different serotypes (N=41), most of which represent wild-type strains circulating in the background population. Third, it was performed in a prospective birth cohort study including a longitudinal sample series starting from cord blood which allowed the timing of the infections to be determined in relation to the time when autoantibodies first appeared.
Fourth, the case and control subjects were matched for the most relevant potential confounders such as HLA-defined diabetes risk, gender, time of birth, age at sampling and the area of residence.
Finally, the results provided by the cross-sectional and longitudinal analyses using different infection criteria were coherent.
We believe that the finding that the three serotypes identified are closely related phylogenetically (Fig. 2) is very significant. Indeed, if the signals detected in this study were due to arbitrary random noise in the methods, it would be unlikely that they would cluster together phylogenetically. Close clustering on the other hand, is precisely what would be expected for serotypes that could be either causative or protective, based on the highly plausible hypothesis of some degree of immunological cross-protection as discussed below.
The outcome reported here is consistent with the diabetogenic role of enteroviruses postulated in the literature and with predictions that can be made in searching for diabetogenic viruses.
Prospective studies have shown that the autoimmune process usually begins at an early age (<3 years) (20, 21) and autoantibodies appear annually in "epidemic" peaks. Despite its virtues, the present study has also limitations. The first relates to the population studied being exclusively from Finland and covering a relatively limited 10-year period.
Consequently, we cannot exclude a timing effect of CBV1 infections or a strain-specific effect of this serotype. A timing effect could also explain the low prevalence of CBV4 serotype which has been linked to type 1 diabetes in previous studies. Accordingly, it will be important to confirm these findings in other populations. The statistical power of the current study allowed the identification of viruses with major risk effects while viruses with weaker effects may have been missed. Adding new data sets would also help to assess further the combined effect of the three identified CBV serotypes. The virus strains used in the neutralization assay represent the most common enterovirus serotypes, (22, 23) but they do not include all serotypes known today (many of them are also difficult to cultivate and to produce cytopatic effect in vitro). Therefore we cannot exclude the possibility that other risk or protective serotypes may have been missed.
The current findings have aspects which fit with causality. First, the CBV1-related risk effect showed logical time relationship -it preceded the initiation of the autoimmune process. In addition, CBV1 infections peaked a few months before autoantibodies first appeared, which overlaps with the previously observed peak in the frequency of enterovirus RNA in serum, (41) 
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This data has been published as a poster presentation in the 17 th Europic meeting 2012 in SaintRaphael, France. The nested study consisted of 183 case/control triplets in which for each case child fulfilling the defined criteria two matched controls were selected. First, the neutralizing antibodies were analyzed in the samples where autoantibodies were detected for the first time (AAB+ date sample) in case children and in the corresponding samples in control children (cross-sectional analysis). Next, neutralizing antibodies were screened in samples from earlier time points (6 months and 12 months before AAB+ date) and in samples taken at birth (cord blood) at the age of 18 months to carry out longitudinal analyses for those enterovirus serotypes which were associated with the modulated diabetes risk at the cross-sectional primary screening step. However, the complete set of follow-up samples was not available from every child, which explains the small variation in the number of samples in different analyses. The information on the diagnosis of type 1 diabetes (T1D date) was utilized to run sub-cohort analyses for those triplets in which the case progressed to type 1 diabetes. The reference group comprises children with the lowest predicted risk being seropositive for the protective serotypes but not for CBV1. OR = odds ratio; 95% CI = 95% confidence interval The sensitive and specific diagnostic criteria analyses were performed as defined in the Methods section. OR = odds ratio; 95% CI = 95% confidence interval.
TABLE 4
The risk of β-cell autoimmunity in children according to their exposure to CBV1 by the age of 18 months (CBV1 seropositive at that age) and presence of protective CBV1 antibodies in cord-blood among 127 case and 254 matched control children. Supplementary Table 7 . Effect of CBV1, CBV3 and CBV6 infections on the risk of β-cell autoimmunity when adjusted for the duration of breast feeding (160 case and 317 control children) or the number of older siblings (177 case and 344 control children). Cross-sectional virus antibody analyses were performed at the time of autoantibody seroconversion. Odds ratios (OR) and 95% confidence intervals (95% CI) are adjusted for the duration of exclusive breast-feeding (time when the child has not received any other nutrients than breast-milk), overall duration of breast feeding (the total time when the child has received breast-milk) and number of older siblings at birth. *This largest group of protective serotypes includes CBV4 since it showed a protective non-significant trend in primary antibody screening and belonged to the same phylogenetic group as CBV1, CBV3 and CBV6 which showed statistically significant effects. **In this category infections occurred in the same sample interval and therefore it is not possible to define their mutual time order.
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